JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operation and Financial Condition
On May4, 2017, Juniper Pharmaceuticals, Inc. (the Company),
issued a press release announcing the financial results for the
three-month period ended March31, 2017, entitled Juniper
Pharmaceuticals Reports First Quarter 2017 Financial and
Operating Results (the Press Release). A copy of the Press
Release is furnished as Exhibit99.1 hereto and is incorporated
herein by reference.
The information contained in this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section18 of the United State Securities Exchange Act
of 1934, as amended, or otherwise subject to the liability of
Section18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any
other filing under the United States Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
references in such filings.
Item5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(b)
On May3, 2017, Frank C. Condella, Jr. notified the Board of
Directors (Board) of Juniper Pharmaceuticals, Inc. (the Company)
that he will not stand for re-election when his current term
expires at the Companys 2017 Annual Meeting of Stockholders. Mr.
Condellas decision was not the result of any disagreement with
the Company on any matter relating to the Companys operations,
policies or practices.
Item9.01. Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release dated May4, 2017, entitled Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results, furnished herewith. |
About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301. JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Recent Trading Information
JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) closed its last trading session 00.00 at 4.65 with 52,480 shares trading hands.
